Research Results of JMT101 of CSPC Published in Subjournal of Nature

June 28, 2023

Recently, the clinical research results of recombinant humanized anti-epidermal growth factor receptor monoclonal antibody injection (JMT101), a Category 1 innovative biological drug independently developed by CSPC, for EGFR-resistant mutation in lung cancer were published in an online article in the internationally renowned authoritative journal Nature Communications (a comprehensive sub-journal of Nature series journals), titled: Phase Ib trial of anti-EGFR JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer.

CSPC is the study's sponsor. Professor Zhang Li, Professor Fang Wenfeng, and Chief Physician Huang Yan from Sun Yat-sen University Cancer Center are the investigator team of the leading institution.

Previous: VOLUNTARY ANNOUNCEMENT - RABEPRAZOLE SODIUM ENTERIC-COATED TABLETS OBTAINS DRUG REGISTRATION APPROVAL

Next: CSPC Attending Beijing-Tianjin-Hebei Pharmaceutical Innovation and Development Conference